Company to Spotlight Comprehensive Hip & Knee Portfolios and Latest Advancements in Robotics, Including the mBôs™ System Following Recent Acquisition...
Winter Park, Florida--(Newsfile Corp. - October 21, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is excited to announce the appointment...
Three Independent Studies Published in “Alzheimer’s Research & Therapy,” “Journal of Alzheimer’s Disease,” and “Radiology” Validate Nexalin’s Non-Invasive Approach with...
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO)...
- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy...
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to...
Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously...
Presentations to Highlight Patient Experience Research, AURA-IPF Phase 2 Trial Design for AP02, and Long-Term Safety Data for AP01BOSTON, Oct....
WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of...
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak®...
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension...
Research Triangle Park, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- First-in-human trial of investigational gene therapy AB-1002 designed to evaluate...
Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™...
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025...
Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to...
Results from Hengrui’s completed Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist with potentially best-in-category weight...
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM,...
Charles “Chip” Romp and Tom Heyman join SynOx’s Board, bringing deep launch, lifecycle, and corporate development expertise as the company...